Awareness about the medical writing profession and the benefits of joining our Ambassador's Program

The Ukrainian translation of the JPS is now available and can be accessed at the following link:

Hungarian: Petronela M. Petrar

French: Laurence Auffret

Your views matter!

If you're attending a workshop at the conference, please fill in the evaluation form: 

- Laura Collada, Marian Hodges, Alison Rapley, Carolina Rojido, Kari Mendonça, and many more.
- If you've missed the workshops, webinars, come and talk to us: Barbara Grossman, Lisa Chamberlain James, and many more.

The members of the EMWA education committee are looking forward to your feedback on the educational programs, and to hear your ideas on how to improve the content and delivery of our educational programs.

EMWA would also like to thank all of the following people for their excellent work in translating the Joint Positions Statement (JPS) on the role of medical writers in the communication of clinical data obtained from medical device studies:

- Laura Collada
- Marian Hodges
- Alison Rapley
- Carolina Rojido
- Kari Mendonça
- and many more.

The JPS aims to provide a clear and consistent understanding of the principles of medical writing and the role of medical writers in the communication of clinical data obtained from medical device studies. The JPS is intended to provide guidance to authors, editors, and medical writers, and to help ensure that medical writers are able to effectively communicate the results of medical device studies to healthcare professionals, patients, and the public.

EMWA Photo Competition:

Then join us at EMWA's medical device symposium on May 3rd in Barcelona.

Patient Involvement in Development and Safe Use of Medicines. The task force reported on the principles of pragmatic patient-centered approaches that should be adopted to improve patient involvement in drug development, pharmacovigilance and risk management. The task force also recommended incorporating patient involvement in the development of post-marketing safety reporting requirements for combination products.

Considerations in Including Pregnant Women in Clinical Trials. The US FDA issued draft guidance on considerations in including pregnant women in clinical trials. The draft guidance includes information to patients and healthcare professionals. The communication in full is available by clicking here.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements. The EMA has also released a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

EMWA News

EMWA highlights successful efforts of a number of people for their excellent work in translating the Joint Positions Statement (JPS) on the role of medical writers in the communication of clinical data obtained from medical device studies. The JPS aims to provide a clear and consistent understanding of the principles of medical writing and the role of medical writers in the communication of clinical data obtained from medical device studies. The JPS is intended to provide guidance to authors, editors, and medical writers, and to help ensure that medical writers are able to effectively communicate the results of medical device studies to healthcare professionals, patients, and the public.

The JPS includes definitions of medical writing, and how it differs from technical writing and literary journalism. The JPS also includes guidance on how to comply with the final rule on transparency and conflict of interest in medical device studies.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements. The EMA has also released a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.

The EMA has published a draft addendum to the Guideline on Pharmacovigilance of combination products. The addendum includes amendments to the existing requirements - First version. This addendum to the Guideline has been developed to provide specific guidance on paediatric clinical development requirements.